20-F/A: Pharming Group Reports Strong Revenue Growth in 2025

Pharming Group N.V. announced significant revenue increases for fiscal year 2025, driven by strong performance in RUCONEST and Joenja sales.

Summary

• Pharming Group N.V. reported total revenues of $376.1 million for the year ended December 31, 2025, a 26.6% increase from $297.2 million in 2024.
• RUCONEST sales in the U.S. market reached $311.7 million, up from $246.6 million in 2024, while Joenja sales globally increased to $58.2 million from $45.0 million in 2024.
• The company's gross profit rose by 26.3% to $330.6 million, primarily due to higher sales volumes.
• Research and development costs increased by 20.7% to $100.4 million, largely due to investments in the napazimone (KL1333) program.
• Net cash generated from operating activities was $54.7 million in 2025, a significant improvement from a net cash used of $1.8 million in 2024.
• The company completed the acquisition of Abliva AB in March 2025, adding napazimone (KL1333) to its pipeline.
• Pharming Group's total employees increased slightly to 409 in 2025 from 404 in 2024.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this filing positively due to strong revenue growth, improved cash flow, and strategic pipeline advancements, despite a minor regulatory delay for Joenja's pediatric indication.

Positives

• Total revenues increased by 26.6% to $376.1 million in 2025.
• RUCONEST sales grew significantly, reaching $311.7 million in the U.S.
• Joenja sales showed strong growth, increasing by 29% to $58.2 million globally.
• Gross profit increased by 26.3% to $330.6 million.
• Net cash from operating activities turned positive at $54.7 million in 2025, a substantial improvement from the previous year.
• The acquisition of Abliva AB strengthens the pipeline with napazimone (KL1333).
• The company has a strong cash position of $179.1 million in cash and marketable securities at year-end 2025.

Negatives

• Research and development costs increased by 20.7% to $100.4 million.
• General and administrative costs increased by 13.2% to $80.0 million.
• Marketing and sales costs increased by 10.3% to $131.0 million.
• Income tax expense increased significantly to $10.3 million in 2025 from $3.3 million in 2024.
• The FDA issued a Complete Response Letter for the pediatric sNDA for Joenja, requesting additional data.

Risks

• The development and commercialization of pharmaceuticals is highly competitive, with RUCONEST facing competition from other HAE treatments.
• The company is heavily dependent on RUCONEST sales in the United States.
• Joenja, a newly approved drug, could develop unexpected safety or efficacy concerns.
• Revenue from approved products depends on market acceptance by physicians, patients, and payors.
• Failure to maintain and grow sales and marketing capabilities, particularly outside the U.S., could adversely affect the business.
• Revenue from approved products depends on adequate coverage and reimbursement levels from governmental authorities and health insurers.
• The costs and timing of clinical trials and approvals involve a high degree of uncertainty.
• Reliance on third parties for preclinical studies and clinical trials could adversely impact the business if they do not perform adequately.
• The company may not be able to obtain or maintain orphan drug exclusivity for its products or product candidates.
• The results from clinical trials may not be sufficiently robust to support marketing approval.
• Cyberattacks could compromise sensitive information and adversely affect the business.
• Contamination in manufacturing processes, shortages of raw materials, or supplier failures could cause delays and impact commercially available goods.
• Dependence on a limited number of suppliers for components and materials could disrupt supply.
• Customer concentration, with a significant portion of revenues from a limited number of customers, poses a risk.
• The company's patents may be challenged, deemed unenforceable, invalidated, or circumvented.
• Changes in trade policies, including tariffs and import/export restrictions, could adversely affect the business.
• The company's assumptions and estimates regarding prevalence and addressable markets for its products may be inaccurate.
• Future legislation regarding energy consumption and waste regulations might hamper operational efficiency.
• Global operations subject the company to significant tax risks.
• The company may be a Passive Foreign Investment Company (PFIC) for U.S. federal income tax purposes, which could result in adverse tax consequences for U.S. Holders.
• ADS holders may not receive distributions on ordinary shares or any value for such distribution if it is illegal or impractical to make them available.
• The company is not obligated to, and does not, comply with all best practice provisions of the Dutch Corporate Governance Code.
• The company has never declared or paid dividends on its ordinary shares and does not anticipate paying dividends in the foreseeable future.

Future Outlook

Pharming Group anticipates continued growth in 2026, focusing on expanding Joenja's market presence through new approvals and pediatric label expansion, reinforcing RUCONEST's position in a competitive market, advancing leniolisib in broader PID indications, and progressing napazimone (KL1333) in its pivotal trial.

Management Comments

• "Patients are at the heart of everything we do. Their insights along with those of caregivers and the scientific community shape our strategy, guide our clinical study designs, and influence how we manage our approved therapies."
• "We execute with discipline and urgency, pursuing strategic growth with focused resource allocation."
• "By strengthening our commercial portfolio and advancing high-value pipeline programs, we aim to deliver sustainable long-term value for patients, healthcare providers, employees, partners, and shareholders."
• "Pharming is committed to advancing care for people living with rare and ultra-rare diseases."
• "Our culture is central to how we execute. We are united by a commitment to improving outcomes for people living with rare and life-threatening conditions."

Industry Context

StockSavvy.ai notes that Pharming Group's performance aligns with the growing trend in the biotechnology sector towards specialized therapies for rare and ultra-rare diseases, where significant unmet medical needs exist. The company's strategic focus on expanding its pipeline and geographic reach reflects a common growth strategy within the industry.

Comparison to Industry Standards

• Pharming's revenue growth of 26.6% in 2025 is strong compared to the average revenue growth of many mid-cap biotechnology companies, which often face challenges in scaling commercial operations.
• The company's R&D expenditure as a percentage of revenue (approximately 27%) is in line with industry standards for companies investing heavily in pipeline development for rare diseases.
• The successful acquisition of Abliva AB demonstrates a strategic approach to pipeline expansion, a common practice in the biotech industry to secure future growth drivers.
• Pharming's focus on specific rare diseases like HAE and APDS, where there are significant unmet needs, is a recognized strategy for differentiation and value creation in the pharmaceutical sector.

Management Changes

Corporate Governance

Legal Proceedings

• Currently not a party to any material legal or administrative proceedings.

Related Party Transactions

• Transactions with BioConnection for fill and finish services amounted to $5.4 million in 2025.
• Pharming holds a 23.0% stake in BioConnection Investments B.V.

Stakeholder Impact

• Shareholders are expected to benefit from strong revenue growth and potential pipeline advancements.
• Patients with HAE and APDS will continue to have access to RUCONEST and Joenja, with efforts to expand access to younger patients.
• Employees may see continued investment in talent and development, alongside restructuring efforts impacting some roles.
• Partners and suppliers will continue to engage with Pharming on manufacturing and development collaborations.

Next Steps

• Advance leniolisib beyond APDS into broader PID populations.
• Progress the pivotal development of napazimone (KL1333) in primary mitochondrial disease.
• Pursue regulatory approvals and launches for Joenja in additional markets.
• Continue to strengthen commercial excellence and patient identification initiatives.
• Maintain reliable product quality and supply assurance for RUCONEST and Joenja.

Key Dates

Recommendation

The company shows strong revenue growth and strategic pipeline development, but the regulatory delay for Joenja's pediatric indication and the ongoing competitive landscape warrant a cautious 'hold' rating. Continued monitoring of pipeline progress and regulatory outcomes is advised.

Keywords

Pharming Group, RUCONEST, Joenja, HAE, APDS, rare diseases, biotechnology, revenue growth, clinical trials, FDA approval, SEC filing, Form 20-F/A